How BioPharma SHAKTI can transform biologics with non-animal models
In 2006, London woke up to a tragedy. Six healthy men involved in a phase I clinical trial of theralizumab, a monoclonal antibody (mAb) designed to treat rheumatoid arthritis, developed multiple organ failure. The antibody triggered an intense immune reaction that the researchers didn’t observe in rhesus monkeys in preclinical tests because their immune cells…
